ProArc Medical News
3 articles
growth-positive
להשקיע בסטארט-אפ ששואף לסייע למיליוני גברים ברחבי העולם
ProArc Medical, an Israeli medical technology company, is developing a revolutionary device called ClearRing to treat enlarged prostate, a common medical issue affecting 40% to 50% of men in their 50s. The device is designed to provide a quick, efficient, and safe procedure for patients, improving their quality of life. The company is currently in an advanced stage of development, having already tested the technology on humans. ProArc Medical is inviting the public to invest in the company through the investment platform ExitValley.
Investment
growth-positive
ProArc Medical Awarded $2.2 Million European Union Grant
ProArc Medical has received a $2.2 million grant from the Horizon 2020 program to support further scientific studies and commercialization of its ClearRing BPH implant. The implant is designed to treat lower urinary tract symptoms caused by enlarged prostate. ProArc aims to provide a simple and reversible procedure that improves the quality of life for men suffering from BPH. The grant from Horizon 2020 is a positive growth impact for the company.
Investment
growth-positive
Hope for men with bladder and prostate problems
Two Israeli startups, ProArc Medical and Elmedical, have developed innovative methods for treating BPH (benign prostatic hyperplasia). ProArc Medicals ClearRing device offers a less invasive and longer-lasting treatment option for BPH, while Elmedicals thermotherapy approach has shown promising results in treating non-muscle invasive bladder cancer (NMIBC). Both companies are experiencing growth in the market for BPH solutions as the population ages. ProArc Medical has started human trials in Europe and plans to test in the United States. Elmedical has treated close to 500 patients and is seeking FDA approval. The market for BPH solutions is increasing, with millions of men suffering from BPH in the United States and European Union.
Customers
